ClinicalTrials.gg
CompletedNCT05599945Updated Oct 9, 2025

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

A Phase 1 interventional study of NNC0581-0001 and Placebo (NNC0581-0001) in Healthy Volunteers and Hepatic Steatosis, sponsored by Novo Nordisk A/S. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Fatty Liver with a site in United Kingdom — 16 open to participants now, 19 under way, 4 of them phase 3. Fatty Liver · United Kingdom.

Enrollment
20th of 34
48 · median 81
Started
2022
with 1 other
Phase 1
5 of 44
2 open now
Registered
28th of 44
by date
Lead sponsor
2 of 44
Novo Nordisk A/S

Among the 44 studies in Fatty Liver with a site in United Kingdom, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 28th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

16 of the 44 studies in Fatty Liver with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Fatty Liver with a site in United Kingdom, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, the pharmacokinetics from single injection (under the skin) of NNC0581-0001 and explores the pharmacodynamics in healthy participants and participants with hepatic steatosis (increased liver fat). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance.NNC0581-0001 is a new medicine which cannot be prescribed by doctors. The study will last about 58 weeks.

03

Conditions studied

  • Healthy Volunteers
  • Hepatic Steatosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria, for healthy participants in Part A:

  • Female of non- or male aged 18-55 years (both inclusive) at the time of signing .
  • (BMI) from 18.5 to 30.0 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, , and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Inclusion criteria for participants with hepatic steatosis in Part B:

  • Female of non-childbearing potential or male aged 18-55 years (both inclusive) at the time of signing informed consent.
  • Body Mass Index (BMI) from 25.0 to 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
  • Hepatic steatosis identified by a score above 248 dB/m by Fibroscan® (Controlled Attenuated Parameter, CAP) at screening.

Exclusion Criteria

  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • For Part A: Any laboratory safety parameters at screening outside the below laboratory ranges, see laboratory provided reference ranges for specific values (re-screening or re-sampling is NOT allowed if the participant has failed one of the exclusion criteria related to laboratory parameters):
  • (ALT) greater than upper normal limit (UNL) plus 10 percent
  • Aspartate aminotransferase (AST) greater than UNL plus 10 percent
  • greater than UNL plus 10 percent
  • Estimated (eGFR) below 90 milliliters per minute per 1.73 square meters (90 mL/min/1.73m\^2)
  • (HbA1c) greater than or equal to 5.7 percent (39 millimole per mole [mmol/mol]) at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Single Dose 1: NNC0581-0001 10 milligram (mg)

    Part A: Healthy participants will receive a single dose of NNC0581-0001 10 mg or matching placebo injection subcutaneously.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

  • Experimental
    Single Dose 2: NNC0581-0001 30 mg

    Part A: Healthy participants will receive a single dose of NNC0581-0001 30 mg or matching placebo injection subcutaneously.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

  • Experimental
    Single Dose 3: NNC0581-0001 90 mg

    Part A: Healthy participants will receive a single dose of NNC0581-0001 90 mg or matching placebo injection subcutaneously.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

  • Experimental
    Single Dose 4: NNC0581-0001 250 mg

    Part A: Healthy participants will receive a single dose of NNC0581-0001 250 mg or matching placebo injection subcutaneously.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

  • Experimental
    Single Dose 5: NNC0581-001 600 mg

    Part B: Participants with hepatic steatosis will receive a single dose of NNC0581-0001 600 mg or matching placebo injection subcutaneously.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

  • Experimental
    Single Dose 6: NNC0581-001 1000 mg

    Part B: Participants with hepatic steatosis will receive a single dose of NNC0581-0001 1000 mg or matching placebo injection subcutaneously.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

Interventions

  • DrugNNC0581-0001

    Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

  • DrugPlacebo (NNC0581-0001)

    Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From dosing (Day 1) until completion of the End of Study Visit at week 52

Secondary outcomes

  1. AUC0-∞: The area under the NNC0581-0001 plasma concentration-time curve from time zero to infinity after a single dose

    Measured in nanogram hour per mililiter (ng\*h/mL).

    Time frame: From dosing (Day 1) to 168 hours after dosing

  2. Cmax: The maximum concentration of NNC0581-0001 in plasma after a single dose

    Measured in nanogram per mililiter (ng/mL).

    Time frame: From dosing (Day 1) to 168 hours after dosing

  3. tmax: The time from dose administration to maximum plasma concentration of NNC0581-0001 after a single dose

    Measured in Hours.

    Time frame: From dosing (Day 1) to 168 hours after dosing

07

Study locations

2 sites
  • Parexel CPRU, Level 7
    Harrow, Middlesex HA1 3UJ, United Kingdom
  • Parexel Research Unit
    Harrow, Middlesex HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2025, 33 months.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Oct 31, 2022
StartActual
Nov 23, 2022
Primary completionActual
Aug 29, 2025
CompletionActual
Aug 29, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05599945
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 31, 2022
Start date
Nov 23, 2022
Primary completion
Aug 29, 2025
Completion
Aug 29, 2025
Last update
Oct 9, 2025

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion